Milestone Pharmaceuticals (MIST) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 116.3% versus a loss of 64.4%. Milestone Pharmaceuticals is the larger company by market cap ($88.7 million vs $85.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | NRXS |
|---|---|---|
| Share price | $0.7121 | $6.77 |
| Market cap | $88.66M | $85.02M |
| 1-day change | -5.96% | -0.88% |
| YTD return | -64.75% | +49.12% |
| 1-year return | -64.39% | +116.29% |
| 5-year return | -87.93% | — |
| EPS (TTM) | $-0.68 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.06 | $9.33 |
| 52-week low | $0.709 | $2.21 |
| Distance from 52-week high | -76.73% | -27.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +722.92% | +62.48% |
| Average volume | 1.40M | 107.27K |
| Shares outstanding | 124.50M | 12.56M |
| Employees | 38 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed MIST by 180.7 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
MIST vs NRXS FAQ
Which is bigger, Milestone Pharmaceuticals or Neuraxis?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $88.66M compared with $85.02M for Neuraxis (NRXS).
Which stock has performed better over the past year, MIST or NRXS?
NRXS returned +116.29% over the past 12 months, compared with -64.39% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Neuraxis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Milestone Pharmaceuticals and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Neuraxis.